CO2022007361A2 - Terapia de combinación para el tratamiento de cáncer cerebral - Google Patents

Terapia de combinación para el tratamiento de cáncer cerebral

Info

Publication number
CO2022007361A2
CO2022007361A2 CONC2022/0007361A CO2022007361A CO2022007361A2 CO 2022007361 A2 CO2022007361 A2 CO 2022007361A2 CO 2022007361 A CO2022007361 A CO 2022007361A CO 2022007361 A2 CO2022007361 A2 CO 2022007361A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
brain cancer
treatment
combination therapy
Prior art date
Application number
CONC2022/0007361A
Other languages
English (en)
Spanish (es)
Inventor
Amy-Lee Bredlau
Israel Lowy
Jeffrey Skolnik
Jian Yan
Bernadette Ferraro
Jewell Walters
Original Assignee
Regeneron Pharma
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Inovio Pharmaceuticals Inc filed Critical Regeneron Pharma
Publication of CO2022007361A2 publication Critical patent/CO2022007361A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
CONC2022/0007361A 2019-11-04 2022-05-27 Terapia de combinación para el tratamiento de cáncer cerebral CO2022007361A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962930417P 2019-11-04 2019-11-04
US202062988102P 2020-03-11 2020-03-11
US202063018060P 2020-04-30 2020-04-30
US202063070987P 2020-08-27 2020-08-27
PCT/US2020/058891 WO2021092019A1 (en) 2019-11-04 2020-11-04 Combination therapy to treat brain cancer

Publications (1)

Publication Number Publication Date
CO2022007361A2 true CO2022007361A2 (es) 2022-06-10

Family

ID=75686760

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0007361A CO2022007361A2 (es) 2019-11-04 2022-05-27 Terapia de combinación para el tratamiento de cáncer cerebral

Country Status (13)

Country Link
US (1) US20210128710A1 (enExample)
EP (1) EP4055033A4 (enExample)
JP (1) JP2023500337A (enExample)
KR (1) KR20220097928A (enExample)
CN (1) CN114901677A (enExample)
AU (2) AU2020380288B2 (enExample)
BR (1) BR112022008164A2 (enExample)
CA (1) CA3156227A1 (enExample)
CO (1) CO2022007361A2 (enExample)
IL (1) IL292462A (enExample)
MX (1) MX2022005345A (enExample)
PH (1) PH12022551078A1 (enExample)
WO (1) WO2021092019A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071633B2 (en) 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CN113447654B (zh) * 2021-07-15 2022-03-22 广州济士源生物技术有限公司 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断前列腺癌产品中的应用
IL310808A (en) * 2021-08-13 2024-04-01 Inovio Pharmaceuticals Inc Combination therapy to treat brain cancer
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US20190048085A1 (en) * 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
JP2019527737A (ja) * 2016-08-09 2019-10-03 アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス
EP3518955A4 (en) * 2016-09-30 2020-10-07 The Wistar Institute Of Anatomy And Biology TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF
EA201990624A1 (ru) * 2017-03-07 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Иммуногенные композиции tert и способы лечения с их использованием
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7216668B2 (ja) * 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
CN109486828B (zh) * 2018-12-27 2022-05-31 广东暨大基因药物工程研究中心有限公司 一种编码重组人白细胞介素12的基因及其应用
EP3969040A1 (en) * 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
JP2022552748A (ja) * 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療

Also Published As

Publication number Publication date
KR20220097928A (ko) 2022-07-08
EP4055033A4 (en) 2023-12-06
CA3156227A1 (en) 2021-05-14
US20210128710A1 (en) 2021-05-06
WO2021092019A1 (en) 2021-05-14
IL292462A (en) 2022-06-01
CN114901677A (zh) 2022-08-12
AU2024202791A1 (en) 2024-05-23
AU2020380288A1 (en) 2022-06-16
MX2022005345A (es) 2022-08-11
JP2023500337A (ja) 2023-01-05
BR112022008164A2 (pt) 2022-07-12
EP4055033A1 (en) 2022-09-14
PH12022551078A1 (en) 2024-06-19
AU2020380288B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
CO2022007361A2 (es) Terapia de combinación para el tratamiento de cáncer cerebral
BR112019021822A2 (pt) Terapia de combinação
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
CY1122858T1 (el) Cd123 δεσμευοντες παραγοντες και χρησεις αυτων
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
SV2018005634A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112018008908A2 (pt) anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
MX2017012552A (es) Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte propragama 1 (pd-1) para el tratamiento del cancer.
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
BR112015023212A2 (pt) tratamento do câncer utilizando anticorpos que se ligam à grp78 da superfície celular
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
BR112018076639A2 (pt) quimioterapias de combinação
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
CO2021005234A2 (es) Métodos de tratamiento